CN1209351C - 用作ccr3受体拮抗剂的n－(4－芳氧基哌啶－1－基烷基)肉桂酰胺化合物 - Google Patents

用作ccr3受体拮抗剂的n－(4－芳氧基哌啶－1－基烷基)肉桂酰胺化合物 Download PDF

Info

Publication number
CN1209351C
CN1209351C CNB018171028A CN01817102A CN1209351C CN 1209351 C CN1209351 C CN 1209351C CN B018171028 A CNB018171028 A CN B018171028A CN 01817102 A CN01817102 A CN 01817102A CN 1209351 C CN1209351 C CN 1209351C
Authority
CN
China
Prior art keywords
alkyl
phenyl
compound
formula
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018171028A
Other languages
English (en)
Chinese (zh)
Other versions
CN1468222A (zh
Inventor
G·巴莱
T·J·豪
D·M·勒格兰德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0024675A external-priority patent/GB0024675D0/en
Priority claimed from GB0120549A external-priority patent/GB0120549D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1468222A publication Critical patent/CN1468222A/zh
Application granted granted Critical
Publication of CN1209351C publication Critical patent/CN1209351C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB018171028A 2000-10-09 2001-10-08 用作ccr3受体拮抗剂的n－(4－芳氧基哌啶－1－基烷基)肉桂酰胺化合物 Expired - Fee Related CN1209351C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0024675.1 2000-10-09
GB0024675A GB0024675D0 (en) 2000-10-09 2000-10-09 Organic compounds
GB0120549.1 2001-08-23
GB0120549A GB0120549D0 (en) 2001-08-23 2001-08-23 Organic compounds

Publications (2)

Publication Number Publication Date
CN1468222A CN1468222A (zh) 2004-01-14
CN1209351C true CN1209351C (zh) 2005-07-06

Family

ID=26245127

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018171028A Expired - Fee Related CN1209351C (zh) 2000-10-09 2001-10-08 用作ccr3受体拮抗剂的n－(4－芳氧基哌啶－1－基烷基)肉桂酰胺化合物

Country Status (12)

Country Link
US (1) US7034042B2 (enExample)
EP (1) EP1330436B1 (enExample)
JP (1) JP4199539B2 (enExample)
CN (1) CN1209351C (enExample)
AT (1) ATE472533T1 (enExample)
AU (1) AU2001295601A1 (enExample)
BR (1) BR0114485A (enExample)
CA (1) CA2423296C (enExample)
DE (1) DE60142484D1 (enExample)
ES (1) ES2348290T3 (enExample)
PT (1) PT1330436E (enExample)
WO (1) WO2002030898A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117387D0 (en) * 2001-07-17 2001-09-05 Novartis Ag Organic compounds
US7524841B2 (en) * 2002-04-25 2009-04-28 Teijin Limited 4,4-disubstituted piperidine derivatives having CCR3 antagonism
ZA200803939B (en) * 2005-11-24 2009-10-28 Eisai R&D Man Co Ltd Morpholine type cinnamide compound

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673684A (en) 1984-04-04 1987-06-16 Terumo Corporation Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient
JPH0660160B2 (ja) 1985-12-13 1994-08-10 テルモ株式会社 アミド誘導体およびこれを含有する抗アレルギ−剤
JPS63139124A (ja) 1986-12-01 1988-06-10 Terumo Corp 腎炎治療剤
JPS63179869A (ja) 1987-01-20 1988-07-23 Dainippon Pharmaceut Co Ltd ピペリジン誘導体
DE19756235A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
EE200100502A (et) 1999-03-26 2002-12-16 Astrazeneca Ab Ühendid
TWI227231B (en) * 2000-07-12 2005-02-01 Novartis Ag 4-benzoyl-piperidine derivatives for treating conditions mediated by CCR-3

Also Published As

Publication number Publication date
PT1330436E (pt) 2010-10-11
AU2001295601A1 (en) 2002-04-22
BR0114485A (pt) 2003-11-18
US7034042B2 (en) 2006-04-25
WO2002030898A1 (en) 2002-04-18
ES2348290T3 (es) 2010-12-02
DE60142484D1 (de) 2010-08-12
EP1330436B1 (en) 2010-06-30
ATE472533T1 (de) 2010-07-15
JP4199539B2 (ja) 2008-12-17
US20040087621A1 (en) 2004-05-06
CA2423296A1 (en) 2002-04-18
EP1330436A1 (en) 2003-07-30
CN1468222A (zh) 2004-01-14
JP2004511467A (ja) 2004-04-15
CA2423296C (en) 2009-12-29

Similar Documents

Publication Publication Date Title
CN1184204C (zh) 用作ccr－3抑制剂的哌啶化合物
CN1950323A (zh) Crth2受体拮抗剂
AU2001281972A1 (en) Piperidine coumpounds for use as CCR-3 inhibitors
CN101228145A (zh) 用于治疗炎性或过敏性病症的有机化合物
CN1956978A (zh) 作为肥大细胞类胰蛋白酶抑制剂的[4－(5－氨基甲基－2－氟－苯基) －哌啶－1－基] －(4－溴－3－甲基－5－丙氧基－噻吩－2－基)-甲酮盐酸盐
JP2009518343A (ja) アリール酢酸およびエステル誘導体、並びに抗炎症剤としてのそれらの使用
CN1209351C (zh) 用作ccr3受体拮抗剂的n－(4－芳氧基哌啶－1－基烷基)肉桂酰胺化合物
CN1097006A (zh) O-芳基吗啡喃的醚类化合物
JP2010265278A (ja) 炎症性およびアレルギー性疾患の処置における、ｃｃｒ−３受容体アンタゴニストとして使用するための１，３−二置換アゼチジン誘導体
CN1378538A (zh) 二氮芳辛－二酮衍生物及其作为类胰蛋白酶抑制剂的应用
CN1227230C (zh) Nmda受体配体的前药
CN1910145A (zh) 用作ccr3受体拮抗剂的吡咯烷衍生物
CN101180260A (zh) 有机化合物
US7259173B2 (en) Derivatives of 3-phenyl-n-(2-(4-benzyl)-piperidin-1-yl)-ethyl)-acrylamid with ccr-3-receptor antagonistic activity for use in the treatment of inflammations and allergic conditions
CN1993352B (zh) 具有ccr3抑制活性的哌嗪衍生物
RU2278856C2 (ru) Производные пиперидина и способ их получения
JP2010516798A (ja) 炎症性またはアレルギー性疾患の処置のためのピペリジン−アセトアミド誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050706

Termination date: 20111008